Park HS, Decker RH, Wilson LD, James BY (2015) Prophylactic cranial irradiation for patients with locally advanced non–small-cell lung cancer at high risk for brain metastases. Clin Lung Cancer 16:292–297

PubMed  Article  Google Scholar 

Han G et al (2016) A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis? Oncotarget 7:56998

PubMed  PubMed Central  Article  Google Scholar 

Miyawaki E et al (2019) Optimal sequence of local and EGFR-TKI therapy for EGFR-mutant non-small cell lung cancer with brain metastases stratified by number of brain metastases. Int J Radiat Oncol Biol Phys 104:604–613

CAS  PubMed  Article  Google Scholar 

Magnuson WJ et al (2016) Impact of deferring radiation therapy in patients with epidermal growth factor receptor–mutant non-small cell lung cancer who develop brain metastases. Int J Radiat Oncol Biol Phys 95:673–679

PubMed  Article  Google Scholar 

Wang W, Song Z, Zhang Y (2018) Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated non-small cell lung cancer patients who develop brain metastasis. Arch Med Sci 14:1298

CAS  PubMed  PubMed Central  Article  Google Scholar 

Magnuson WJ et al (2017) Management of brain metastases in tyrosine kinase inhibitor–naïve epidermal growth factor receptor–mutant non-small-cell lung cancer: a retrospective multi-institutional analysis. J Clin Oncol 35:1070–1077

CAS  PubMed  Article  Google Scholar 

Chiou G-Y et al (2021) Combined stereotactic radiosurgery and tyrosine kinase inhibitor therapy versus tyrosine kinase inhibitor therapy alone for the treatment of non-small cell lung cancer patients with brain metastases. J Neurosurg 1:1–8

Google Scholar 

Gerosa M, Nicolato A, Foroni R, Tomazzoli L, Bricolo A (2005) Analysis of long-term outcomes and prognostic factors in patients with non-small cell lung cancer brain metastases treated by gamma knife radiosurgery. J Neurosurg 102:75–80

PubMed  Article  Google Scholar 

Borghetti P et al (2019) Concomitant radiotherapy and TKI in metastatic EGFR-or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group. Radiol Med (Torino) 124:662–670

Article  Google Scholar 

Lee JH et al (2019) Cranial irradiation for patients with epidermal growth factor receptor (EGFR) mutant lung Cancer who have brain metastases in the era of a new generation of EGFR inhibitors. Oncologist 24:e1417

CAS  PubMed  PubMed Central  Article  Google Scholar 

Jia F, Cheng X, Zeng H, Miao J, Hou M (2019) Clinical research on stereotactic radiosurgery combined with epithermal growth factor tyrosine kinase inhibitors in the treatment of brain metastasis of non-small cell lung cancer. J BUON 24:578–584

PubMed  Google Scholar 

Yang W-C et al (2018) Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery. Radiother Oncol 126:368–374

CAS  PubMed  Article  Google Scholar 

Fan Y et al (2017) Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases. Sci Rep 7:1–10

Article  CAS  Google Scholar 

Shin SM et al (2016) Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery. J Neurooncol 126:483–491

CAS  PubMed  Article  Google Scholar 

Wang TJ et al (2015) Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation? Neuro Oncol 17:1022–1028

PubMed  PubMed Central  Article  CAS  Google Scholar 

Planchard D et al (2018) Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv192–iv237

CAS  PubMed  Article  Google Scholar 

Stinchcombe TE (2016) The use of EGFR tyrosine kinase inhibitors in EGFR wild-type non-small-cell lung cancer. Curr Treat Options Oncol 17:1–11

CAS  Article  Google Scholar 

Tomasini P et al (2017) EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice. Eur Respir J 50:1700514

PubMed  Article  CAS  Google Scholar 

Li K, Yang M, Liang N, Li S (2017) Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: perplexity and solution. Oncol Rep 37:1347–1358

CAS  PubMed  PubMed Central  Article  Google Scholar 

Colclough N et al (2021) Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs. Clin Cancer Res 27:189–201

CAS  PubMed  Article  Google Scholar 

Kim Y-J et al (2019) Caveolin-1 enhances brain metastasis of non-small cell lung cancer, potentially in association with the epithelial-mesenchymal transition marker SNAIL. Cancer Cell Int 19:1–13

Article  CAS  Google Scholar 

Ten Berge D et al (2020) Referral patterns and outcome of patients with synchronous brain metastases from non-small cell lung cancer treated with gamma knife radiosurgery in a third-line treatment centre in The Netherlands–a retrospective analysis. Clin Oncol 32:52–59

Article  Google Scholar 

Singh R et al (2020) Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: a systematic review and meta-analysis of multidisciplinary approaches. Radiother Oncol 144:165–179

CAS  PubMed  Article  Google Scholar 

Zhang Q et al (2016) Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis. Thoracic cancer 7:648–654

CAS  PubMed  PubMed Central  Article  Google Scholar 

Wang N et al (2019) Osimertinib (AZD9291) increases radio-sensitivity in EGFR T790M non-small cell lung cancer. Oncol Rep 41:77–86

CAS  PubMed  Google Scholar 

Johung KL et al (2013) A clinical model for identifying radiosensitive tumor genotypes in non-small cell lung cancer. Clin Cancer Res 19:5523–5532

CAS  PubMed  Article  Google Scholar 

Ciuleanu T et al (2012) Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 13:300–308

CAS  PubMed  Article  Google Scholar 

Franchino F, Rudà R, Soffietti R (2018) Mechanisms and therapy for cancer metastasis to the brain. Front Oncol 8:161

PubMed  PubMed Central  Article  Google Scholar 

Zhao N, Zhang X-C, Yan H-H, Yang J-J, Wu Y-L (2014) Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials. Lung Cancer 85:66–73

PubMed  Article  Google Scholar 

Garassino MC et al (2013) Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 14:981–988

CAS  PubMed  Article  Google Scholar 

Yuan W et al (2019) TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription. Cell Death Dis 10:1–11

Article  CAS  Google Scholar 

Higginbotham JN et al (2011) Amphiregulin exosomes increase cancer cell invasion. Curr Biol 21:779–786

CAS  PubMed  PubMed Central  Article  Google Scholar 

Zeng Y et al (2020) CDK5 activates hippo signaling to confer resistance to radiation therapy via upregulating TAZ in lung cancer. Int J Radiat Oncol Biol Phys 108:758–769

PubMed  Article  Google Scholar 

Tohme S, Simmons RL, Tsung A (2017) Surgery for cancer: a trigger for metastases. Can Res 77:1548–1552

CAS  Article  Google Scholar 

Gow C-H et al (2008) Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res 14:162–168

CAS  PubMed  Article  Google Scholar 

Lee H-L et al (2012) EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases. Radiat Oncol 7:1–8

CAS  Article  Google Scholar 

Jiang T et al (2016) EGFR TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases. J Thorac Oncol 11:1718–1728

PubMed  Article  Google Scholar 

Blackhall FH, Shepherd FA, Albain KS (2005) Improving survival and reducing toxicity with chemotherapy in advanced non-small cell lung cancer. Treat Respir Med 4:71–84

CAS  PubMed  Article  Google Scholar 

Kano H et al (2010) T1/T2 matching to differentiate tumor growth from radiation effects after stereotactic radiosurgery. Neurosurgery 66:486–492

PubMed  Article  Google Scholar 

Terakawa Y et al (2008) Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 49:694–699

PubMed  Article  Google Scholar 

Ozsunar Y et al (2010) Glioma recurrence versus radiation necrosis?: a pilot comparison of arterial spin-labeled, dynamic susceptibility contrast enhanced MRI, and FDG-PET imaging. Acad Radiol 17:282–290

PubMed  Artic